CCI
CPRX

Columbus Circle Investors’s Catalyst Pharmaceutical CPRX Stock Holding History

Columbus Circle Investors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-358,078
Closed -$419K – 261
2016
Q1 		$419K Sell
358,078
-60,306
-14% -$93.6K ﹤0.01% 254
2015
Q4 		$1.02M Sell
418,384
-146,275
-26% -$419K 0.01% 252
2015
Q3 		$1.69M Buy
564,659
+356,066
+171% +$1.54M 0.01% 235
2015
Q2 		$861K Buy
+208,593
New +$831K 0.01% 255

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Columbus Circle Investors's CPRX Position: Q2 2016 in Review

Columbus Circle Investors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2016, closing a stake of 358,078 shares — an estimated $419K sold.

Columbus Circle Investors first reported a position in CPRX in Q2 2015 and held it in 4 quarters. The position peaked at $1.69M in Q3 2015. 62 funds tracked by Wall St. Rank hold CPRX as of Q2 2016.

  • Columbus Circle Investors reported no remaining Catalyst Pharmaceutical position as of Q2 2016 after selling out during the quarter.
  • Columbus Circle Investors sold 358,078 Catalyst Pharmaceutical shares in Q2 2016, an estimated $419K.
  • Columbus Circle Investors first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 4 quarters.
  • Columbus Circle Investors's Catalyst Pharmaceutical position peaked at $1.69M in Q3 2015.
  • 62 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2016.

Based on Columbus Circle Investors's 13F filing for Q2 2016, filed 2 Aug 2016.